Grotte D, Mattox V, Brubaker R
Exp Eye Res. 1985 Jan;40(1):23-33. doi: 10.1016/0014-4835(85)90105-8.
When fluorescein is administered systemically, it is metabolized to form a fluorescent compound, fluorescein monoglucuronide. The molar fluorescent intensity of this compound is less than that of fluorescein but its fluorescent intensity compared to fluorescein varies considerably depending on the wavelength employed for excitation. Several hours after oral or intravenous administration the conjugate can become the dominant fluorophore in the plasma. When fluorescein is administered systemically and fluorescent intensity is measured in the eye, it is necessary to determine which compound is being measured since the time courses of the plasma concentrations and the permeability of the ocular barrier of each compound may not be the same. A technique suitable for measuring the relative concentration of each fluorophore in ocular tissues in vivo is suggested.
当荧光素经全身给药时,它会代谢形成一种荧光化合物——荧光素单葡萄糖醛酸苷。该化合物的摩尔荧光强度低于荧光素,但其与荧光素相比的荧光强度会因用于激发的波长不同而有很大差异。口服或静脉给药数小时后,该缀合物可成为血浆中的主要荧光团。当荧光素经全身给药并在眼部测量荧光强度时,由于每种化合物的血浆浓度时间进程和眼屏障通透性可能不同,因此有必要确定正在测量的是哪种化合物。本文提出了一种适用于在体内测量眼部组织中每种荧光团相对浓度的技术。